RGEN
Repligen Corporation
103.14
1 x 97.28
4 x 112.11
bid
ask
-
0.24
0.23%
03:46 PM
timesize
Ytd -37.06%
1y -16.32%
103.06
day range
107.75
100.99
52 week range
175.77
Open 104.46 Prev Close 103.38 Low 103.06 High 107.75 Mkt Cap 5.82B
Vol 1.77M Avg Vol 1.02M EPS 0.91 P/E 113.31 Forward P/E 41.92
Beta 1.09 Short Ratio 5.69 Inst. Own 116.19% Dividend N/A Div Yield N/A
Ex Div Date N/A Earning 08-04 50-d Avg 119.25 200-d Avg 137.97 1yr Est 179.78
Earning
Date For Estimate Reported Surprise surprise %
2026-05-05 2026-03 0.38 0.48 0.1 26.32%
2026-02-24 2025-12 0.44 0.49 0.05 11.36%
2025-10-28 2025-09 0.42 0.46 0.04 9.52%
2025-07-29 2025-06 0.4 0.37 -0.03 -7.50%
2025-04-29 2025-03 0.35 0.39 0.04 11.43%
2025-02-20 2024-12 0.41 0.44 0.03 7.32%
Upgrade / Downgrade
Date Firm Action From To
2026-05-06 JP Morgan Upgrade Overweight Overweight
2026-05-06 Barclays Upgrade Overweight Overweight
2026-04-20 Canaccord Genuity Upgrade Hold Hold
2026-04-17 Roth Capital Upgrade Buy
2026-04-14 Barclays Upgrade Overweight Overweight
2026-04-06 Evercore ISI Group Upgrade Outperform Outperform
Profile
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification and quality control of biological drugs, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems. The company offers its products under the OPUS, XCell, XCell ATF, TFDF, KrosFlo, SIUS, ProConnex, Spectra/Por, NGL-Impact, SoloVPE, FlowVPE, RPM, XO, Metenova MixOne, and AVIPure and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
Insider Holder
Date Name Relation Quantity Description
2026-03-04 BYLUND JAMES Chief Operating Officer 25.42K Stock Award(Grant)
2025-12-16 DAWES KAREN A Director 91.82K Sale
2025-12-30 DOUGLASS BRIAN ROBB Officer 8.54K Stock Award(Grant)
2025-05-14 EGLINTON MANNER CARRIE Director 4.47K Stock Award(Grant)
2026-03-04 GARLAND JASON K. Chief Financial Officer 20.09K Stock Award(Grant)
2025-11-12 HUNT ANTHONY JOHN Director 83.70K Conversion of Exercise of derivative security
Institution Ownership
Report Date Organization Position Value Percentage
2026-03-30 Blackrock Inc. 5.99M 619.56M 10.62%
2025-12-30 Price (T.Rowe) Associates Inc 4.60M 475.45M 8.15%
2025-12-30 FMR, LLC 2.87M 296.48M 5.08%
2025-12-30 United Capital Financial Advisors, LLC 2.77M 286.45M 4.91%
2026-03-30 Vanguard Capital Management LLC 2.40M 247.75M 4.25%
2026-03-30 Vanguard Portfolio Management LLC 2.31M 238.30M 4.09%
Fund Ownership
Report Date Organization Position Value Percentage
2026-03-30 iShares Trust-iShares Core S&P Mid-Cap ETF 1.75M 181.26M 3.11%
2025-12-30 VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund 1.69M 174.27M 2.99%
2025-12-30 VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund 1.21M 125.47M 2.15%
2025-12-30 T. Rowe Price New Horizons Fund, Inc. 912.48K 94.33M 1.62%
2026-02-27 MFS Series Trust IV-MFS Mid Cap Growth Fund 866.36K 89.56M 1.54%
2025-12-30 T. Rowe Price All-Cap Opportunities Fd., Inc.-T. Rowe Price All-Cap Op 748.46K 77.38M 1.33%